BIOMARIN PHARMACEUTICAL INC
Close on Oct 19, 2026
- Market cap
- $10.63B
- P/E (TTM)
- 143.9
- Dividend yield
- –
Earnings
Next report expected Oct 26, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $990.00M | $0.23 | $1.20 |
| Q1 FY2026 Ended Mar 31, 2026 | May 4, 2026 | After market close | $766.00M | $0.54 | $0.76 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 23, 2026 | After market close | $875.00M | $-0.24 | $0.46 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 27, 2025 | After market close | $776.00M | $-0.16 | $0.12 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 4, 2025 | After market close | $825.00M | $1.23 | $1.44 |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | After market close | $745.00M | $0.95 | $1.13 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 19, 2025 | After market close | $747.00M | $0.64 | $0.92 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 29, 2024 | After market close | $746.00M | $0.55 | $0.91 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 24, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Non-GAAP Diluted EPSnon-GAAP | 2026 Full-Year | $4.90 to $5.10 | New |
| Total Revenues | 2026 Full-Year | $3.88B to $3.93B | Raised |
| Metabolic Conditions | 2026 Full-Year | $2.73B to $2.78B | Lowered |
| VOXZOGO | 2026 Full-Year | $1.00B to $1.05B | Lowered |
| Other Revenues | 2026 Full-Year | $100.00M to $125.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Biomarin Pharmaceutical filed with the SEC
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia,
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
BioMarin Reports Second Quarter 2026 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Report of Independent Registered Public Accounting Firm
Other events · EX-99.1 to Form 8-K/A
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Other events · EX-99.2 to Form 8-K/A
BioMarin Reports First Quarter 2026 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
BioMarin Completes Acquisition of Amicus Therapeutics
Material agreement · Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
BioMarin Announces Closing of Private Offering of Senior Notes
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of
Regulation FD disclosure · EX-99.1 to Form 8-K
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Risks Related to the Acquisition
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Hardy Greg Friberg Chief Executive Officer Chief R&D Officer BioMarin Pharmaceutical Inc. January 12, 2026
Results of operations · EX-99.1 to Form 8-K
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance 1 for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
Results of operations · EX-99.1 to Form 8-K
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
Results of operations · EX-99.1 to Form 8-K
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
Results of operations · EX-99.1 to Form 8-K
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
Results of operations · EX-99.1 to Form 8-K
BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance
Results of operations · EX-99.1 to Form 8-K
BioMarin Reports Record Financial Results for the First Quarter 2024
Results of operations · EX-99.1 to Form 8-K
EFiled: Mar 27 2024 12:01PM EDT
Other events · EX-99.1 to Form 8-K
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
Results of operations · EX-99.1 to Form 8-K
BioMarin Announces Governance Enhancements and
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
Results of operations · EX-99.1 to Form 8-K
BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
Results of operations · EX-99.1 to Form 8-K
BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues
Results of operations · EX-99.1 to Form 8-K
BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO ® and Steady Growth of Enzyme Business
Results of operations · EX-99.1 to Form 8-K
Conference January 9, 2023 Transforming Lives Through Genetic Discovery J.J. Bienaime Chairman and Chief Executive Officer
Results of operations · EX-99.1 to Form 8-K
BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24%
Results of operations · EX-99.1 to Form 8-K
BioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance
Results of operations · EX-99.1 to Form 8-K
BioMarin Announces Record Revenues in First Quarter 2022
Results of operations · EX-99.1 to Form 8-K
BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
BioMarin Sells Priority Review Voucher for $110 Million
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K